Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.43 |
| ▸ | NFATC1 | O95644 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | SLC34A1 | Q06495 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041950 | 0.84 | ADORA2A (0.50) | ADORA2AADORA2BDYRK1ANFATC1GSK3B | |
| Ammonia Solution, Strong SCHEMBL29096508 | 0.82 | ADORA2A (0.48) | ADORA2AADORA2BDYRK1ANFATC1GSK3B | |
| SCHEMBL25971676 | 0.78 | DYRK1A (0.39) | ADORA2ADYRK1ANFATC1GSK3BADORA3 | |
| SCHEMBL659962 | 0.78 | DYRK1A (0.42) | ADORA2ADYRK1ANFATC1GSK3BADORA3 | |
| SCHEMBL21894106 | 0.78 | GSK3B (0.42) | ADORA2ADYRK1ANFATC1GSK3BADORA3 | |
| SCHEMBL23145661 | 0.78 | DYRK1A (0.42) | ADORA2ADYRK1ANFATC1GSK3BADORA3 | |
| SCHEMBL21893785 | 0.76 | DYRK1A (0.41) | ADORA2ADYRK1ANFATC1GSK3BADORA3 | |
| SCHEMBL21893439 | 0.76 | DYRK1A (0.40) | ADORA2ADYRK1ANFATC1GSK3BADORA3 | |
| SCHEMBL11916066 | 0.76 | DYRK1A (0.40) | ADORA2ADYRK1ANFATC1GSK3BADORA3 | |
| Formamide SCHEMBL29063839 | 0.75 | ELANE (0.44) | ADORA2AADORA2BDYRK1ANFATC1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| WO-2016084866-A1 | NOVEL DIAZABICYCLO DERIVATIVE | 持田製薬株式会社 | 2016-06-02 | — | — | WO | disclosed |
| EP-2867222-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002057-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ADORA2A 1225/4885ADORA2B 1464/4885DYRK1A 2576/4885 |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | ADORA2A 405/4885ADORA2B 315/4885DYRK1A 2483/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | ADORA2A 678/4885ADORA2B 554/4885DYRK1A 2246/4885 |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | SULT2A1, PSEN1, PSEN2 | ADORA2A 1431/4885ADORA2B 860/4885DYRK1A 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.